Clinical Trials Logo
  1. Home
  2. Viral Infection
  3. NCT04423692
  4. Details
NCT04423692 Clinical Trial

Knowledge About Covid-19 Infection in Pregnant Women

Viral Infection Clinical Trial

Official title:
Knowledge About Covid-19 Infection in Pregnant Women

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04423692
Other study ID # Knowledge about covid 19
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2020
Est. completion date August 20, 2020

Study information
Verified date July 2020
Source Aljazeera Hospital
Contact Mahmoud Alalfy
Phone 01002611058
Email mahmoudalalfy@ymail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Covid 19 is a pandemic infection developed in late 2019

Description:

It developed in China Then spread worl wide

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date August 20, 2020
Est. primary completion date August 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 42 Years
Eligibility Inclusion Criteria:

- pregnant women

Exclusion Criteria:

- non pregnant women

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• labs
A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy

Locations
Country Name City State
Egypt Aljazeera( Al Gazeera) hospital Giza

Sponsors (1)
Lead Sponsor Collaborator
Aljazeera Hospital

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary The number of pregnant women who have knowledge about covid-19 The proper knowledge about covid-19 one month
See also
  Status Clinical Trial Phase
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Not yet recruiting NCT05953233 - School Inner City Air Study N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Completed NCT01570283 - ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus Phase 1/Phase 2
Not yet recruiting NCT01159470 - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children N/A
Recruiting NCT02532452 - Third Party Viral Specific T-cells (VSTs) Phase 2
Recruiting NCT05246098 - REVIVe: Frailty, Rehabilitation, and Outcomes in Critically Ill Adult and Pediatric Survivors of COVID-19 or ARI
Recruiting NCT05603650 - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract N/A
Completed NCT04525456 - Immune Responses With Reduxium N/A
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Completed NCT04267809 - Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection Phase 2
Completed NCT00341081 - Validation of Self-Reported Needle Sharing Among Injection Drug Users N/A
Recruiting NCT04088916 - Proviral DNA as a Target for HIV-1 Resistance Analysis
Terminated NCT04401410 - Anti-SARS Cov-2 T Cell Infusions for COVID 19 Phase 1
Terminated NCT00952185 - Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Active, not recruiting NCT04254991 - A Controlled, Blinded Study to Validate the Diagnostic Accuracy and Assess the Clinical Utility of a Host-response Based Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the ED With Suspicion of Acute Infection
Completed NCT05897801 - Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO
Terminated NCT02696291 - Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects Phase 1